ES2170771T3 - Atenuacion de un epitopo inmunodominante de un antigeno para su utilizacion en vacunas e inmunoterapias para vegetales, animales y humanos. - Google Patents

Atenuacion de un epitopo inmunodominante de un antigeno para su utilizacion en vacunas e inmunoterapias para vegetales, animales y humanos.

Info

Publication number
ES2170771T3
ES2170771T3 ES94925937T ES94925937T ES2170771T3 ES 2170771 T3 ES2170771 T3 ES 2170771T3 ES 94925937 T ES94925937 T ES 94925937T ES 94925937 T ES94925937 T ES 94925937T ES 2170771 T3 ES2170771 T3 ES 2170771T3
Authority
ES
Spain
Prior art keywords
epithope
immunodominant
antigen
immunotherapies
vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94925937T
Other languages
English (en)
Inventor
Robert R Garrity
Peter L Nara
Jaap Goudsmit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Health and Human Services
Original Assignee
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Department of Health and Human Services filed Critical United States Department of Health and Human Services
Application granted granted Critical
Publication of ES2170771T3 publication Critical patent/ES2170771T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCION SUMINISTRA UNA VACUNA QUE PUEDE ADMINISTRARSE A UN MAMIFERO PARA PROVOCAR LA INMUNO-PROTECCION EN EL MAMIFERO CONTRA UN ORGANISMO PATOGENICO QUE TENGA UN EPITOPO INMUNODOMINANTE. LA VACUNA INCLUYE UNA FORMA MODIFICADA DEL ANTIGENO EN EL CUAL SE LOCALIZA EL EPITOPO INMUNODOMINANTE. EN ESTA FORMA MODIFICADA, EL EPITOPO INMUNODOMINANTE ES INMUNOHUMECTADO POR CUALQUIERA DE ENTRE UN NUMERO DE TECNICAS. LOS EJEMPLOS DE TECNICAS DE INMUNO-HUMECTACION INCLUYE LA ADICION DE ZONAS DE GLICOSILACION N- ENLAZADAS, EL CAMBIO DE LA CARGA DE RED DEL EPITOPO Y LA SUSTITUCION CON UNA SECUENCIA TOLERADA. LA VACUNA TAMBIEN INCLUYE UN PORTADOR FARMACOLOGICAMENTE ACEPTABLE.
ES94925937T 1993-08-20 1994-08-19 Atenuacion de un epitopo inmunodominante de un antigeno para su utilizacion en vacunas e inmunoterapias para vegetales, animales y humanos. Expired - Lifetime ES2170771T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/109,934 US5585250A (en) 1993-08-20 1993-08-20 Dampening of an immunodominant epitope of an antigen for use in plant, animal and human compositions and immunotherapies

Publications (1)

Publication Number Publication Date
ES2170771T3 true ES2170771T3 (es) 2002-08-16

Family

ID=22330363

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94925937T Expired - Lifetime ES2170771T3 (es) 1993-08-20 1994-08-19 Atenuacion de un epitopo inmunodominante de un antigeno para su utilizacion en vacunas e inmunoterapias para vegetales, animales y humanos.

Country Status (11)

Country Link
US (2) US5585250A (es)
EP (1) EP0714444B1 (es)
JP (2) JP3851938B2 (es)
AT (1) ATE211767T1 (es)
AU (1) AU700786B2 (es)
CA (2) CA2623540A1 (es)
DE (1) DE69429625T2 (es)
DK (1) DK0714444T3 (es)
ES (1) ES2170771T3 (es)
PT (1) PT714444E (es)
WO (1) WO1995006124A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585250A (en) * 1993-08-20 1996-12-17 The United States Of America As Represented By The Department Of Health & Human Services Dampening of an immunodominant epitope of an antigen for use in plant, animal and human compositions and immunotherapies
WO1997017372A1 (en) * 1995-11-03 1997-05-15 The Binding Site Limited Production of antibodies, and medical uses involving antibodies
US6936249B1 (en) * 1998-04-15 2005-08-30 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
US6642011B2 (en) * 1998-04-15 2003-11-04 Genencor International, Inc. Human protease and use of such protease for pharmaceutical applications and for reducing the allergenicity of non-human proteins
US6835550B1 (en) * 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
US20020182180A1 (en) * 1998-05-29 2002-12-05 Yutaro Kaneko Method for inducing immunity to viruses
CA2348822A1 (en) * 1998-10-30 2000-05-11 Novozymes A/S Glycosylated proteins having reduced allergenicity
US6759216B1 (en) * 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
US7078043B2 (en) 1999-04-20 2006-07-18 Medical Research Council Malaria vaccine
DE10055786A1 (de) * 2000-11-10 2002-05-29 Henkel Kgaa Haftungsverstärker für monomerfreie reaktive Polyurethane
AU774286B2 (en) 1999-11-29 2004-06-24 Henkel Kommanditgesellschaft Auf Aktien Adhesion promoters for monomer-free reactive polyurethanes
US6673580B2 (en) * 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
AU2003300870A1 (en) * 2002-12-11 2004-06-30 The Scripps Research Institute Immunogenic mutant human immunodeficiency virus gp120 polypeptides, and methods of using same
US7514539B2 (en) * 2004-04-26 2009-04-07 Centocor, Inc. Epitope directed selection of antibodies to murine tissue factor
US7790405B2 (en) * 2004-04-26 2010-09-07 Centocor, Inc. Solution phase biopanning method using engineered decoy proteins
AU2005271893A1 (en) * 2004-07-10 2006-02-16 Alexion Pharmaceuticals, Inc. Antibodies against cancer produced using masked cancer cells as immunogen
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
EP1868652A2 (en) * 2005-04-05 2007-12-26 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Method for shielding functional sites or epitopes on proteins
US20090162383A1 (en) * 2006-12-26 2009-06-25 Padlan Eduardo A Method for designing vaccines against constantly mutating pathogens
EP2254593B1 (en) * 2008-02-21 2018-09-05 Biological Mimetics, Inc. Immunogenic influenza composition
US9782472B2 (en) * 2008-10-04 2017-10-10 The Regents Of The University Of California Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity
NZ604943A (en) * 2008-12-02 2014-08-29 Consejo Nac Invest Cient Tec Modified protozoan expressing at least two variable surface proteins (vsp), a vaccine comprising it and procedures, uses, and methods thereof
US20100189727A1 (en) * 2008-12-08 2010-07-29 Tegopharm Corporation Masking Ligands For Reversible Inhibition Of Multivalent Compounds
WO2011028963A2 (en) * 2009-09-03 2011-03-10 Biological Mimetics, Inc. Immunogenic hiv composition
CA2787974A1 (en) 2010-01-24 2011-07-28 Biological Mimetics, Inc. Immunogenic influenza composition
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
AU2011344126B2 (en) 2010-12-13 2016-11-10 The University Of Utah Research Foundation Vaccine antigens that direct immunity to conserved epitopes
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP3269728B1 (en) 2011-10-20 2020-12-16 The Government of The United States of America as represented by The Secretary, Department of Health and Human Services Dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
JP6467672B2 (ja) 2012-07-17 2019-02-13 メリアル インコーポレイテッド 弱毒ブタインフルエンザワクチンならびにその製造方法および使用方法
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
SG10201806481XA (en) * 2014-02-19 2018-09-27 Emergent Biosolutions Canada Inc Marburg monoclonal antibodies
CA2952741A1 (en) 2014-06-26 2015-12-30 Janssen Vaccines & Prevention B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
JP7614841B2 (ja) * 2018-04-03 2025-01-16 サノフイ 抗原性呼吸器合胞体ウイルスポリペプチド
EP3773698A1 (en) 2018-04-03 2021-02-17 Sanofi Ferritin proteins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041376A (en) * 1988-12-09 1991-08-20 The Board Of Regents Of The University Of Texas System Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins
US5585250A (en) * 1993-08-20 1996-12-17 The United States Of America As Represented By The Department Of Health & Human Services Dampening of an immunodominant epitope of an antigen for use in plant, animal and human compositions and immunotherapies

Also Published As

Publication number Publication date
AU700786B2 (en) 1999-01-14
US5585250A (en) 1996-12-17
EP0714444A1 (en) 1996-06-05
CA2623540A1 (en) 1995-03-02
JP2006104216A (ja) 2006-04-20
WO1995006124A1 (en) 1995-03-02
US5853724A (en) 1998-12-29
DE69429625T2 (de) 2002-09-12
DK0714444T3 (da) 2002-04-29
CA2169764C (en) 2008-04-15
JPH09501933A (ja) 1997-02-25
DE69429625D1 (de) 2002-02-14
PT714444E (pt) 2002-07-31
JP3851938B2 (ja) 2006-11-29
EP0714444B1 (en) 2002-01-09
AU7569294A (en) 1995-03-21
CA2169764A1 (en) 1995-03-02
ATE211767T1 (de) 2002-01-15

Similar Documents

Publication Publication Date Title
ES2099211T3 (es) Conjugados citomoduladores de miembros de parejas de union especifica.
ES2530769T3 (es) Métodos para la activación de células T in vivo por células dendríticas pulsadas con antígeno
GT200300180A (es) Vacunas para enfermedades reproductoras del ganado
ES2179105T3 (es) Adyuvantes proteinicos.
CO4560552A1 (es) Antagonistas de receptores de taquicininas no peptidicos
ES2152222T3 (es) Sulfonamidas, su preparacion y su uso como medicamento e intermedio.
ES2079063T3 (es) Utilizacion de analogos de vitamina d en el tratamiento del acne.
AR005703A1 (es) Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen
ES2163508T3 (es) Compresa sanitaria con segmento de nucleo desplazable independientemente.
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
UY34901A (es) ?monohidrato cristalino, procedimiento para su preparacion ysu utilizacion para la preparacion de un medicamento?.
ES2188783T3 (es) Empleo de una tienotriazolodiazepina para aumentar los niveles de apolipoproteina a-i.
GT200200028A (es) Compuestos de ppar
ES2152421T3 (es) Vacunas de conjugados polisacarido neumococcico-neumolisina recombinante para la inmunizacion contra las infecciones neumococcicas.
ES2087061T3 (es) Utilizacion de ribosido o ribotido de aica para la fabricacion de un medicamento contra la crisis cardiaca o el infarto de miocardio en los pacientes que sufren de ateroesclerosis.
AR025750A1 (es) Vacunas
ES2144151T3 (es) Benzotiazepinas hipolipidemicas.
ES2054860T5 (es) Derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion y su utilizacion como medicamentos.
ES2133311T3 (es) Vacunas antifertilidad de salmonella avirulenta recombinante.
AR035500A1 (es) Uso de clorpromazina y pentamidina para la fabricacion de medicamentos, composicion farmaceutica y paquete farmaceutico que comprenden clorpromazina y pentamidina.
MX9206817A (es) Nuevos azoheterociclilmetil-cromanos, procedimiento para su obtencion y medicamento que los contiene.
PT714444E (pt) Atenuacao de um epitopo imunodominante de um antigenio para utilizacao em vacinas e imunoterapias para plantas, animais e homens
ES2053778T3 (es) Procedimiento para la obtencion de derivados del tiazol.
UY27186A1 (es) Formulación farmacéutica
AR026059A1 (es) Virus de plantas modificadas y metodos para su uso

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 714444

Country of ref document: ES